Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 8Radiotherapy 7Cisplatin 6pembrolizumab 4Fluorouracil 4Surgical Procedures, Operative 3Radiation 3Oxaliplatin 3Levoleucovorin 3Leucovorin 3Esophagectomy 3Drug Therapy 3Carboplatin 3lenvatinib 2durvalumab 2Taxes 2TP protocol 2Radiotherapy, Intensity-Modulated 2Nivolumab 2Neoadjuvant Therapy 2Irinotecan 2Capecitabine 2trifluridine tipiracil drug combination 1tislelizumab 1palbociclib 1osimertinib 1obinutuzumab 1nedaplatin 1naptumomab estafenatox 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Squamous Cell Carcinoma × cixutumumab × Clear all
NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡